{"preliminary_commentary":{"by_channel":{"x_thread":38,"youtube":3,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02893332\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"Sindas","nct_id":"NCT02893332","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=sindas-nct02893332. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"Sindas","arms":[{"description":"Newly diagnosed Patients will be placed on EGFR-TKI, ,Gefitinib 250mg po qd or Tarceva 150mg po qd for their metastatic EGFR-mutant stage IV oligometastatic disease.\n\nThe oligometastatic disease will not receive SBRT","label":"TKI without SBRT","type":"ACTIVE_COMPARATOR"},{"description":"experimental: Oligometastatic Non-Small Cell Lung Cancer Newly diagnosed patients will be placed on EGFR-TKI, Gefitinib 250mg po qd or Tarceva 150mg po qd, for their metastatic EGFR-mutant stage IV oligometastatic disease. All patients will TKI, Gefitinib 250mg po qd or Tarceva 150mg po qd, and SBRT at the same time.\n\nSBRT to up to 5 sites. The SBRT dose range from 5 Gy per fraction to 8 Gy per fraction. SBRT deliver within 5 fractions.","label":"TKI with SBRT","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2020-08-30","type":"ACTUAL"},"conditions":["Stage IV EGFR Mutated Non-Small Cell Lung Cancer"],"enrollment":{"count":200,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Radiation: SBRT","otherNames":[],"type":"RADIATION"},{"name":"TKI (Gefitinib or Tarceva )","otherNames":[],"type":"DRUG"}],"last_update":"2021-02-03","lead_sponsor":"Sichuan Provincial People's Hospital","official_title":"Tyrosine-kinase Inhibitor （TKI） With or Without SBRT in Newly Diagnosed EGFRm Advanced Staged Lung Adenocarcinoma","overall_status":"TERMINATED","phases":["PHASE3"],"primary_completion_date":{"date":"2020-08-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression free survival","timeFrame":"4 years"}],"references":[{"citation":"Wang XS, Bai YF, Verma V, Yu RL, Tian W, Ao R, Deng Y, Zhu XQ, Liu H, Pan HX, Yang L, Bai HS, Luo X, Guo Y, Zhou MX, Sun YM, Zhang ZC, Li SM, Cheng X, Tan BX, Han LF, Liu YY, Zhang K, Zeng FX, Jia L, Hao XB, Wang YY, Feng G, Xie K, Lu Y, Zeng M. Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer. J Natl Cancer Inst. 2023 Jun 8;115(6):742-748. doi: 10.1093/jnci/djac015.","pmid":"35094066","type":"DERIVED"}],"start_date":{"date":"2016-01-15","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Stereotactic Body Radiation Therapy (SBRT) in Newly Diagnosed Advanced Staged Lung Adenocarcinoma (Sindas)","url":"https://clinicaltrials.gov/study/NCT02893332"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/sindas-nct02893332"}